Risk of SARS-CoV-2 infection, hospitalization and death for COVID-19 in people with Parkinson's disease or parkinsonism over a 15-month period: a cohort study.
COVID-19
Parkinson’s disease
cohort studies
frail elderly
parkinsonism
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
16 Jul 2022
16 Jul 2022
Historique:
revised:
30
06
2022
received:
09
04
2022
accepted:
13
07
2022
entrez:
16
7
2022
pubmed:
17
7
2022
medline:
17
7
2022
Statut:
aheadofprint
Résumé
The patterns of long term risk of SARS-CoV-2 infection, hospitalization for COVID-19 and related death are uncertain in people with Parkinson's disease (PD) or parkinsonism (PS). The aim of the study was to quantify these risks compared to a control population cohort, during the period March 2020-May 2021, in Bologna, northern Italy. ParkLink Bologna cohort (759 PD; 192 PS) and controls (9,226) anonymously matched (ratio 1:10) for sex, age, district, comorbidity were included. Data were analysed in the whole period and in the two different pandemic waves (March-May 2020 and October 2020-May 2021). Adjusted hazard ratio of SARS-CoV-2 infection was 1.3 (95% CI 1.04-1.7) in PD and 1.9 (1.3-2.8) in PS compared to the controls. The trend was detected in both the pandemic waves. Adjusted hazard ratio of hospitalization for COVID-19 was 1.1 (95% CI 0.8-1.7) in PD and 1.8 (95% CI 0.97-3.1) in PS. A higher risk of hospital admission was detected in PS only in the first wave. The 30-day mortality risk after hospitalization was higher (p=0.048) in PS (58%) than in PD (19%) and controls (26%). Compared with controls, after adjustment for key covariates, people with PD and PS showed a higher risk of SARS-CoV-2 infection throughout the first 15 months of the pandemic. COVID-19 hospitalization risk was increased only in people with PS and only during the first wave. This group of patients was burdened by a very high risk of death after infection and hospitalization.
Sections du résumé
BACKGROUND
BACKGROUND
The patterns of long term risk of SARS-CoV-2 infection, hospitalization for COVID-19 and related death are uncertain in people with Parkinson's disease (PD) or parkinsonism (PS). The aim of the study was to quantify these risks compared to a control population cohort, during the period March 2020-May 2021, in Bologna, northern Italy.
METHOD
METHODS
ParkLink Bologna cohort (759 PD; 192 PS) and controls (9,226) anonymously matched (ratio 1:10) for sex, age, district, comorbidity were included. Data were analysed in the whole period and in the two different pandemic waves (March-May 2020 and October 2020-May 2021).
RESULTS
RESULTS
Adjusted hazard ratio of SARS-CoV-2 infection was 1.3 (95% CI 1.04-1.7) in PD and 1.9 (1.3-2.8) in PS compared to the controls. The trend was detected in both the pandemic waves. Adjusted hazard ratio of hospitalization for COVID-19 was 1.1 (95% CI 0.8-1.7) in PD and 1.8 (95% CI 0.97-3.1) in PS. A higher risk of hospital admission was detected in PS only in the first wave. The 30-day mortality risk after hospitalization was higher (p=0.048) in PS (58%) than in PD (19%) and controls (26%).
CONCLUSIONS
CONCLUSIONS
Compared with controls, after adjustment for key covariates, people with PD and PS showed a higher risk of SARS-CoV-2 infection throughout the first 15 months of the pandemic. COVID-19 hospitalization risk was increased only in people with PS and only during the first wave. This group of patients was burdened by a very high risk of death after infection and hospitalization.
Identifiants
pubmed: 35841385
doi: 10.1111/ene.15505
pmc: PMC9350080
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
This article is protected by copyright. All rights reserved.
Références
Neurology. 1996 Jul;47(1):1-9
pubmed: 8710059
Front Aging Neurosci. 2022 Mar 03;14:821235
pubmed: 35317529
Mov Disord Clin Pract. 2021 May 03;8(6):859-867
pubmed: 34226870
Aging (Albany NY). 2020 Dec 22;12(24):24522-24534
pubmed: 33353888
Mov Disord. 2021 May;36(5):1049-1057
pubmed: 33942924
Mov Disord. 2019 Nov;34(11):1711-1721
pubmed: 31449711
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Rev Med Virol. 2022 Mar;32(2):e2278
pubmed: 34260773
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Alzheimers Dement. 2021 Nov;17(11):1818-1831
pubmed: 33881211
J Neurol. 2010 Jan;257(1):5-14
pubmed: 19669613
J Neurol Neurosurg Psychiatry. 2012 Oct;83(10):1027-9
pubmed: 22960987
Parkinsonism Relat Disord. 2021 Jun;87:155-161
pubmed: 33931304
Mov Disord. 2020 Aug;35(8):1287-1292
pubmed: 32449528
Lancet Psychiatry. 2020 May;7(5):387-388
pubmed: 32353267
Arch Gerontol Geriatr. 2021 Mar-Apr;93:104299
pubmed: 33285424
Geriatr Nurs. 2021 Sep-Oct;42(5):1230-1239
pubmed: 33824009
Mov Disord. 2017 Jun;32(6):853-864
pubmed: 28467028
J Neurol. 2014 Aug;261(8):1575-83
pubmed: 24888315
Geriatrics (Basel). 2021 Jan 26;6(1):
pubmed: 33530357
Neurology. 2008 Aug 26;71(9):670-6
pubmed: 18725592
Lancet Infect Dis. 2020 Jul;20(7):776-777
pubmed: 32224313
Neurol Sci. 2017 Aug;38(8):1373-1380
pubmed: 28497309
Arch Neurol. 1999 Jan;56(1):33-9
pubmed: 9923759
Mov Disord. 2014 Nov;29(13):1583-90
pubmed: 24976103
Euro Surveill. 2020 Jun;25(22):
pubmed: 32524949
Mov Disord. 2020 Nov;35(11):1914-1915
pubmed: 32954522
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):308-314
pubmed: 33412823
Nature. 2022 Mar;603(7902):587-598
pubmed: 35090163
Parkinsonism Relat Disord. 2017 Jan;34:7-14
pubmed: 28341224
J Parkinsons Dis. 2021;11(2):445-454
pubmed: 33749619
Mov Disord. 2021 Jan;36(1):1-10
pubmed: 33196119
Mov Disord. 2020 Jul;35(7):1089-1093
pubmed: 32484584
PLoS One. 2014 Dec 29;9(12):e116123
pubmed: 25546308
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211039709
pubmed: 34404266
Geriatr Gerontol Int. 2021 Feb;21(2):172-177
pubmed: 33340212
Eur J Neurol. 2022 Jul 16;:
pubmed: 35841385
J Am Med Dir Assoc. 2021 Feb;22(2):440-445.e2
pubmed: 32723531
PLoS Med. 2015 Oct 06;12(10):e1001885
pubmed: 26440803
Mov Disord. 2004 Jun;19(6):630-40
pubmed: 15197700
J Neurol Neurosurg Psychiatry. 2017 May;88(5):402-411
pubmed: 28250027
BMC Neurol. 2022 Jan 7;22(1):15
pubmed: 34996388
Neurol Sci. 2022 Feb;43(2):775-783
pubmed: 34787753
EClinicalMedicine. 2021 Oct;40:101111
pubmed: 34514362
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 22;8(5):
pubmed: 34301818
Eur J Neurol. 2021 Dec;28(12):3925-3937
pubmed: 34411383
BMC Infect Dis. 2021 Aug 21;21(1):855
pubmed: 34418980
JAMA Neurol. 2017 Jul 1;74(7):839-846
pubmed: 28505261
J Am Med Dir Assoc. 2021 Oct;22(10):1969-1988
pubmed: 34428466
Parkinsonism Relat Disord. 2020 Nov;80:7-9
pubmed: 32920322
BMJ. 2021 Sep 17;374:n2244
pubmed: 34535466